Nabla is building a comprehensive AI assistant designed to streamline clinical workflows, reduce administrative burden, and enhance patient care. Nabla produces AI-generated clinical notes in seconds from any encounter with seamless EHR integration. Powered by proprietary, clinical LLMs, Nabla is available across 35 languages and 55 specialties for both in person and tele-health visits. Nabla is already being used by 85,000+ clinicians and has been chosen by 130+ organizations. | Nabla is building a comprehensive AI assistant designed to streamline clinical workflows, reduce administrative burden, and enhance patient care. Nabla produces AI-generated clinical notes in seconds from any encounter with seamless EHR integration. Powered by proprietary, clinical LLMs, Nabla is available across 35 languages and 55 specialties for both in person and tele-health visits. Nabla is already being used by 100,000+ clinicians and has been chosen by 150+ organizations.
JPB SYSTEME
JPB Système is the leading manufacturer of efficiency-enhancing technologies and self-locking systems. Pioneers in the aeronautics industry, we are now applying our expertise to the theme park and amusement sectors with a solution for monitoring the tightening of screwed assemblies. | JPB Système, holder of 15+ patents, designs and manufactures self-locking solutions, including fastening systems and loosening-detection sensors for critical equipment in harsh environments. Built for vibration, shock, and temperature changes, our products secure assemblies, enable real-time detection, and reduce maintenance time. Based in France, with subsidiaries in Poland and the USA, and recognized as “Best Supplier” by OEMs as Safran. JPB Système also works with Parc Astérix.
INSTITUT CURIE
The Institut Curie, France’s leading cancer center, brings together a research center of international renown and a state-of-the-art hospital complex that treats all types of cancer, including the rarest. Founded in 1909 by Marie Curie, the Institut Curie brings together nearly 4,000 researchers, physicians, and healthcare professionals across three sites (Paris, Saint-Cloud, and Orsay) around its three core missions: care, research, and education. As a foundation recognized as being of public interest and authorized to receive donations and bequests, the Institut Curie is able, thanks to the support of its donors, to accelerate discoveries and thereby improve treatments and patients’ quality of life. | The Curie Institute is France’s leading center for cancer research and treatment. Founded in 1921 by Marie Curie, it brings together a world-renowned research center and a state-of-the-art hospital group that treats all types of cancer, including the rarest forms. Spread across three sites (Paris, Saint-Cloud, and Orsay) the Institute unites 3,800 professionals, including researchers, physicians, and healthcare staff, around its three core missions: research, care, and knowledge sharing.
INA GRM
INA GRM is a pioneering institution established in 1958 by Pierre Schaeffer and dedicated to research and promotion of experimental electroacoustic music, INA GRM (Groupe de Recherches Musicales de l’Institut National de l’Audiovisuel) has authored digital audio effects for more than 30 years.
Iktos
Founded in 2016, Iktos is a global leader in artificial intelligence and robotics for drug discovery. Its generative AI technology designs molecules in-silico, optimized to meet all key success criteria of a discovery project. Iktos combines AI-driven molecular design with robotic synthesis and biological testing, to accelerate drug discovery. With over 60 successful projects to date, Iktos supports its clients through software and strategic drug discovery collaborations. Iktos is also advancing its own pipeline of drug candidates in oncology, obesity and metabolism, inflammatory and autoimmune diseases. The company completed a €15.5M Series A financing round in 2023, co-led by M Ventures and Debiopharm Innovation, with participation from Omnes Capital. In 2024, Iktos acquired Synsight, strengthening its platform with cutting-edge cellular imaging and high-content biological screening capabilities. In 2025, Iktos was awarded a €2.5M grant from the European Innovation Council (EIC) Accelerator, with potential follow-on funding of €5M, to advance its integrated AI and robotics platform. In January 2026, Iktos signed its largest Drug Discovery collaboration to date with Servier, for a total potential deal value of over €1 billion euros. For more information, visit Iktos.ai.
IINSTITUT PASTEUR
Institut Pasteur is a non-for-profit private foundation dedicated to the prevention and treatment of diseases. 1) Institut Pasteur offers opportunities for R&D collaborations and in-licensing agreements to Health Tech companies (Pharmas, Biotechs, Diagnostics, Imaging …). Fields of interest include diagnostic, vaccine, therapeutic and research tools, technologies for: Infectious diseases , Immunology and inflammatory disorders, Neurosciences and neurodegenerative diseases, Oncology, Genetic diseases, Orphan diseases, AI, computational biology, bioimage analysis …. and many other innovations and expertise 2) Institut Pasteur support the creation of spinoff companies (36 to date). In this context, Institut Pasteur support their business development and the opportunities for Investor to invest in its portfolio companies 3) Institut Pasteur acts also as a fund of fund investor (LP)
ICOSA
ICOSA is an IP Law firm dedicated to Healthcare (Biotech/Pharma/Medtech), located in Paris, Lyon (France) and Brussels (Belgium). Expanding quickly, ICOSA is now a reknown name among the specialized IP Law Firms. | ICOSA is a European intellectual property firm dedicated to healthcare (Biology/biotech, chemistry, medtech/AI). ICOSA’s business vision enables them to offer customized services to companies and investors, assisting them in the management and valorization of their intellectual property assets, including patents, trademarks, designs, copyright, and domain names. As a human company which gathers 80 professionals, ICOSA is agile and responsive. Its teams are composed of European IP attorneys (EPO and EUIPO) and French IP attorneys (INPI) holding doctorates and/or engineering or law degrees from top French or European schools and universities. Leveraging their scientific expertise and technical and legal skills, ICOSA’s experts master the specific challenges of intellectual property for each innovation or creation. Their attentive and highly available approach enables them to support their clients on a daily basis in decision-making and business growth. | ICOSA is an Intellectual Property Firm founded in 2009, specializing in supporting companies in the Healthcare sector across the Life Sciences (Biology-Biotech, Chemistry, Pharma) and Tech (Medtech/Medical Devices, AI/Software) fields. ICOSA’s business-oriented approach allows it to offer tailored services to companies and investors, helping them manage and enhance the value of their intellectual property assets (patents, trademarks, designs, copyrights, domain names, and contracts). A human-scale company with a team of 85 professionals, ICOSA is agile and responsive. Its teams include European patent and trademark attorneys (EPO and EUIPO) and French IP attorneys, all holding PhDs and/or engineering or law degrees from top-tier French or European schools and universities. With deep scientific expertise and strong technical and legal skills, ICOSA’s experts have a comprehensive understanding of the IP challenges specific to each innovation or creation. Their attentiveness and availability allow them to support clients daily in decision-making and business growth.
GYRDIS
GYRDIS is a manufacturer of innovative foodservice equipment for the retail and food industry. Our flagship product, the Gyropancakes, is an automatic french pancakes-making machine designed for in-store use in supermarkets, bakeries, and food courts. With over 1,500 installations over the world, GYRDIS serves major retail groups. The Gyropancakes enables retailers to make and sell fresh, authentic French pancakes directly in-store with minimal training and labor. The machine automates the batter spreading, cooking, and rolling process, allowing staff to produce high-quality crêpes in less than 15 seconds. Customers can enjoy freshly made crêpes, filled with sweet or savory ingredients, creating an engaging and profitable in-store food experience. As demand for fresh, on-the-go, and experiential food options continues to rise, GYRDIS offers a turnkey solution that helps retailers increase foot traffic, boost margins, and enhance customer satisfaction. Our machines are easy to operate, require limited maintenance, and can fit to different store formats. GYRDIS is now expanding into the U.S. market with a localized version of the Gyropancakes tailored to American retail environments. Visit us at IBIE to discover how you can bring a taste of France to your store and turn french pancakes into your next best-selling product.